Javascript must be enabled to continue!
A volumetric analysis of timing and duration of T2/FLAIR changes on MRI following radiation therapy in patients with low-grade IDH-mutant glioma
View through CrossRef
Abstract
Background
Patients with IDH-mutant low-grade glioma (LGG) can achieve many years of survival with radiation (RT) and chemotherapy. There is a risk of overtreatment and negative treatment side effects if these patients are unnecessarily retreated due to perceived tumor progression in the absence of true tumor regrowth. A better understanding of volumetric postradiation FLAIR changes will help with the clinical interpretation of disease progression/treatment effect and will help guide management decisions. We conducted this research to characterize the changes in MRI FLAIR hyperintensity that occur in LGG patients following RT, to better understand the radiation-treatment effects or “pseudoprogression” that occurs in the absence of true tumor regrowth.
Methods
Serial MRI scans of patients with LGG were reviewed, including pre-RT and for 2.5 years post-RT. Segmentation for volumetric analysis was performed with manual supervision using ITK-SNAP (open-source segmentation software). Descriptive statistics are reported.
Results
Sixteen patients with histologic grade 2 gliomas were included. 159 MRI scans were segmented using ITK-SNAP (median 9.5 MRIs/patient). Nine of 16 MRIs showed decreasing FLAIR volume immediately post-RT, while 7/16 showed increasing FLAIR volume. After the initial post-RT MRI, 12/16 patients had MRIs with an increase in FLAIR volume sometime during the first year. The FLAIR volume stabilized or decreased a median of 18.4 months and a mean of 15.0 months post-RT.
Conclusions
FLAIR hyperintensity changes on MRI are highly variable in the first 1.5 years post-RT in low-grade glioma, but after 1.5 years, FLAIR volumes stabilize and decrease, likely indicating the inflection point where post-RT pseudoprogression stabilizes.
Oxford University Press (OUP)
Title: A volumetric analysis of timing and duration of T2/FLAIR changes on MRI following radiation therapy in patients with low-grade IDH-mutant glioma
Description:
Abstract
Background
Patients with IDH-mutant low-grade glioma (LGG) can achieve many years of survival with radiation (RT) and chemotherapy.
There is a risk of overtreatment and negative treatment side effects if these patients are unnecessarily retreated due to perceived tumor progression in the absence of true tumor regrowth.
A better understanding of volumetric postradiation FLAIR changes will help with the clinical interpretation of disease progression/treatment effect and will help guide management decisions.
We conducted this research to characterize the changes in MRI FLAIR hyperintensity that occur in LGG patients following RT, to better understand the radiation-treatment effects or “pseudoprogression” that occurs in the absence of true tumor regrowth.
Methods
Serial MRI scans of patients with LGG were reviewed, including pre-RT and for 2.
5 years post-RT.
Segmentation for volumetric analysis was performed with manual supervision using ITK-SNAP (open-source segmentation software).
Descriptive statistics are reported.
Results
Sixteen patients with histologic grade 2 gliomas were included.
159 MRI scans were segmented using ITK-SNAP (median 9.
5 MRIs/patient).
Nine of 16 MRIs showed decreasing FLAIR volume immediately post-RT, while 7/16 showed increasing FLAIR volume.
After the initial post-RT MRI, 12/16 patients had MRIs with an increase in FLAIR volume sometime during the first year.
The FLAIR volume stabilized or decreased a median of 18.
4 months and a mean of 15.
0 months post-RT.
Conclusions
FLAIR hyperintensity changes on MRI are highly variable in the first 1.
5 years post-RT in low-grade glioma, but after 1.
5 years, FLAIR volumes stabilize and decrease, likely indicating the inflection point where post-RT pseudoprogression stabilizes.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
IDH and 1p19q Diagnosis in Diffuse Glioma from Preoperative MRI Using Artificial Intelligence
IDH and 1p19q Diagnosis in Diffuse Glioma from Preoperative MRI Using Artificial Intelligence
Abstract
Background
Isocitrate dehydrogenase (IDH) mutation and 1p19q codeletion are important beneficial prognosticators in gl...
Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma
Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma
Background: Isocitrate dehydrogenase (IDH) mutant is one of the most robust and important genetic aberrations in glioma. However, the underlying regulation mechanism of long non-co...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Abstract 7081: Enzyme hyperactivation to target isocitrate dehydrogenase mutations
Abstract 7081: Enzyme hyperactivation to target isocitrate dehydrogenase mutations
Abstract
Somatic mutations in isocitrate dehydrogenase (IDH) enzymes are hallmarks of acute myeloid leukemia (AML), glioma, and several other cancers. Mutations i...
Rare dual‐genotype IDH mutant glioma: Review of previously reported cases and two new cases of true “oligoastrocytoma”
Rare dual‐genotype IDH mutant glioma: Review of previously reported cases and two new cases of true “oligoastrocytoma”
In 2016, the World Health Organization (WHO) eliminated “oligoastrocytoma” from the classification of central nervous system (CNS) tumors, in favor of an integrated histologic and ...
Abstract 1133: Molecular evolution patterns in primary versus recurrent adult gliomas: A multi-institutional study from Project GENIE
Abstract 1133: Molecular evolution patterns in primary versus recurrent adult gliomas: A multi-institutional study from Project GENIE
Abstract
Introduction:
Gliomas are the most common primary malignant brain tumors in adults, with high recurrence rates despite ...

